Dr. Arora on Novel Therapies in CLL

Video

In Partnership With:

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses novel therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses novel therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

There are 3 classes of therapy in CLL, explains Arora—–BTK inhibitors, PI3K-delta inhibitors, and BCL-2 inhibitors. Ibrutinib (Imbruvica) is a BTK inhibitor that was first approved in 2014 for patients who had received at least 1 prior therapy as well as those with a 17p deletion. In 2016, the label was expanded to include frontline use. The approval was based on data from the RESONATE-2 trial, which compared the BTK inhibitor with chlorambucil in 269 treatment-naïve patients with CLL or small lymphocytic lymphoma 65 years or older.

In an ongoing phase III study (NCT02477696; ACE-CL-006), ibrutinib is being compared head-to-head with the second-generation BTK inhibitor, acalabrutinib (Calquence) in previously treated patients. Acalabrutinib has not shown as severe of side effects as seen with ibrutinib, explains Arora. Based on the results of the trial, acalabrutinib may become a suitable frontline option for patients who cannot tolerate ibrutinib.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD